MOC.WAR Molecure S.A.
- Market cap
- PLN 144M
- P/E
- -
- P/B
- 1.64x
- ROE
- -12.5%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MOC.WAR undervalued?
Graham numberThe Graham number of Molecure S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Molecure S.A. fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-12.5%), below 10%.
ROA 1/1
Return on assets (-11.2%) is above the industry median (-18.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (50.5%) is above the industry median (2.6%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (4.1%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 9.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.6x) is below the industry median (3.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Molecure S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Pha…
Full company profileMolecure S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Molecure S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.60K | 6.00K | 3.00K | 2.81K | 123M | 1.17M | 7.51M | 3.65M | 2.92M | - | 337K |
| Gross Profit | -50.2K | -98.9K | -147K | -144K | 84.5M | -2.77M | -21.3K | -4.10M | -490K | - | -13.1M |
| Operating Income | -2.52M | -2.58M | -5.12M | -4.83M | 73.7M | -13.8M | -37.7M | -32.1M | -33.6M | -22.0M | -15.8M |
| EBITDA | -2.32M | -2.31M | -4.38M | -3.85M | 73.9M | -13.3M | -31.8M | -25.5M | -27.4M | -19.0M | -13.4M |
| Net Income | -2.42M | -2.40M | -3.78M | -4.16M | 68.0M | -13.6M | -36.0M | -28.4M | -31.3M | -15.7M | -12.6M |
| EPS | -0.15 | -0.20 | -0.28 | -0.31 | 4.90 | -0.98 | -2.56 | -1.69 | -1.55 | -0.77 | -0.54 |
| Balance Sheet | |||||||||||
| Total Assets | 15.5M | 34.6M | 86.0M | 85.7M | 153M | 152M | 91.8M | 112M | 114M | 94.4M | 113M |
| Total Liabilities | 2.51M | 4.85M | 4.12M | 6.56M | 10.1M | 10.4M | 11.6M | 11.3M | 10.3M | 6.99M | 11.4M |
| Shareholders' Equity | 13.0M | 29.7M | 81.9M | 79.1M | 147M | 141M | 80.2M | 101M | 103M | 87.4M | 101M |
| Cash & Short-term Investments | 2.53M | 13.2M | 51.9M | 34.0M | 121M | 102M | 65.6M | 64.0M | 18.2M | 16.3M | 24.9M |
| Total Debt | - | - | - | 3.83M | 5.23M | 6.01M | 6.41M | 7.14M | 7.23M | 5.29M | 4.14M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.44M | -600K | -4.89M | -7.11M | 57.4M | -13.5M | -34.1M | -23.3M | -57.0M | -19.4M | -2.55M |
| Capital Expenditure | 14.6M | 24.0M | 27.4M | 34.9M | 2.09M | 2.45M | 3.32M | 362K | 23.8M | 3.00 | 0.00 |
| Free Cash Flow | -16.0M | -24.6M | -32.3M | -42.0M | 55.3M | -32.3M | -43.8M | -23.7M | -80.8M | -19.4M | -2.55M |
| Ratios | |||||||||||
| ROE | -18.6% | -8.1% | -4.6% | -5.3% | 46.2% | -9.7% | -44.8% | -28.1% | -30.3% | -17.9% | -12.5% |
| ROA | -15.6% | -7.0% | -4.4% | -4.9% | 44.3% | -9.0% | -39.2% | -25.3% | -27.5% | -16.6% | -11.2% |
| Net Profit Margin | -36,731.7% | -40,072.2% | -125,905.3% | -148,127.2% | 55.3% | -1,168.1% | -478.5% | -776.8% | -1,071.8% | - | -3,748.0% |
| Debt to Equity | - | - | - | 0.05x | 0.04x | 0.04x | 0.08x | 0.07x | 0.07x | 0.06x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Molecure S.A. dividends
Molecure S.A. has not paid dividends in the last 9 fiscal years.
Who owns Molecure S.A.
- Insiders 29.29%
- Institutions 9.31%
- Public & others 61.40%
- Shares outstanding 24.7M
- Free float 16.3M
Molecure S.A. company profile
- Company name
- Molecure S.A.
- Ticker
- MOC.WAR
- ISIN
- PLONCTH00011
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Fiscal year end
- December
- Address
- Zwirki i Wigury 101, Warsaw, Poland, 02-089
- Phone
- 48 225 52 67 24
- Website
- molecure.com
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Molecure S.A. management
8- Dr. Marcin Jan Szumowski Ph.D.Co-Founder, CEO & President of Management Board
- Dr. Zbigniew ZaslonaChief Scientific Officer & Member of Management Board
- Ms. Agnieszka Rajczuk-SzczepanskaHR Director
- Dr. Adam Golebiowski Ph.D.Co-Founder & VP of Research Chemistry
- Mr. Jacek Olczak Ph.D.Co-Founder & Head of Medicinal Chemistry
- Ms. Monika CzarneckaFinance Director
- Ms. Magdalena TyszkiewiczHead of CMC
- Mr. Dariusz Stencel M.D., Ph.D.Chief Medical Officer